Biosimilar Insulins (Generally) Won't Need Comparative Clinical Immunogenicity Data, US FDA Says

 
• By Michael Cipriano
insulin hormone vials-single use syringe_1200x675
The US FDA is proposing streamlining development of biosimilar/interchangeable insulins.

More from Biosimilars

More from Biosimilars & Generics